

- Terminally ill patient (*Cont.*):  
 managing last stages for, 66–67  
 physical symptoms of, 59, 60t  
 anorexia, 69t  
 apnea, 69t  
 constipation, 61, 62t  
 dehydration, 69t  
 delirium, 69t  
 dysphagia, 69t  
 dyspnea, 62, 62t  
 fatigue, 63–64, 69t  
 incontinence, 69t  
 nausea and vomiting, 61–62  
 pain, 60–61  
 psychological symptoms of, 60t, 63  
 delirium, 64–65, 65t  
 depression, 64–65  
 insomnia, 65  
 social needs of, 65–66  
 withholding/withdrawal of care of, 66–67
- Terminal restlessness, 169
- Terminal weaning, 66–67
- Terrorism  
 chemical. *See* Chemical terrorism  
 microbial/biological. *See* Bioterrorism  
 radiation. *See* Radiation terrorism
- Terson's syndrome, 40e-3
- TERT gene mutations, 664–665
- Testes/testicles, 2357  
 biopsy of, 2361  
 development of, 2357–2358, 2357f  
 disorders of. *See also* Male reproductive system disorders  
 acquired defects, 2365–2366  
 adrenal rest tumors, 2328, 2328f, 2356  
 alcohol use disorder and, 2725  
 cancer. *See* Testicular cancer  
 in Carney's complex, 2343  
 cryptorchidism, 588, 2355, 2365  
 in disorders of sex development. *See* 46,XY disorders of sex development  
 in Klinefelter's syndrome, 2365. *See also* Klinefelter's syndrome  
 mass, 588  
 neuroendocrine tumors, 564  
 torsion, 871–872, 2365  
 dysgenetic, 2353, 2354t  
 in lepromatous leprosy, 1125  
 in mumps infection, 231e-2, 231e-3  
 physical examination of, 2360  
 referred pain from, 105  
 regulation of function of  
 androgen in, 2358–2359, 2358f, 2359f, 2359t  
 hypothalamic-pituitary-testis axis in, 2358, 2358f  
 seminiferous tubules in, 2359–2360  
 structure of, 2357–2358
- Testicular cancer, 588  
 clinical features of, 588  
 epidemiology of, 588  
 etiology of, 588  
 genetic considerations in, 588  
 global considerations in, 588  
 incidence of, 588  
 metastatic, 408  
 paraneoplastic syndromes in, 609t, 614t, 619  
 pathology of, 588  
 risk classification in, 590–591, 591t  
 staging of, 588, 589f  
 treatment of  
 chemotherapy for advanced disease, 590  
 HSCT, 139e-6  
 infertility after, 592  
 late consequences of, 623, 624t  
 nonseminoma, 589f, 590  
 postchemotherapy surgery, 591  
 risk-directed chemotherapy, 590–591, 591t  
 salvage chemotherapy, 591  
 seminoma, 589f, 590  
 tumor markers in, 588
- Testicular dysgenesis, 2353, 2354t
- Testicular feminization syndrome. *See* Androgen insensitivity syndrome (AIS)
- Testis-determining factor (*TDF*), 439
- Testosterone  
 age-related changes in levels of, 7e-1, 7e-1f, 75, 75f  
 assays of, 2360–2361  
 bioavailable, 2361  
 in hirsutism, 332–333  
 in men with prostate cancer, 7e-4–5  
 reference values for, 2763t  
 synthesis of, 2309f, 2359f  
 total, tests of, 2360  
 transport and metabolism of, 2358–2359, 2359f  
 unbound, measurement of, 2361
- Testosterone cypionate, 2370t, 2371
- Testosterone enanthate, 2370t, 2371
- Testosterone-lowering drugs. *See* Androgen deprivation therapy (ADT)
- Testosterone therapy  
 abuse of. *See* Anabolic-androgenic steroid (AAS) abuse  
 for adult hypopituitarism, 2259t  
 adverse effects of, 2371, 2372, 2372t  
 for androgen deficiency, 2370–2371  
 contraindications to, 2372, 2372t  
 for delayed puberty, 2363  
 efficacy of, 2372  
 for erectile dysfunction, 328  
 formulations of, 2370t  
 buccal adhesive, 2371  
 in development, 2371  
 gel, 2370t, 2371  
 implants, 2371  
 injectable, 2370t, 2371  
 not available in U.S., 2371  
 oral, 2370t, 2371  
 transdermal patch, 2370t, 2371  
 gonadotropin inhibitors and, 2372  
 for hypogonadism, 2261  
 indications for, 2371–2372  
 for male contraception, 2372  
 in men with history of prostate cancer, 7e-5, 2372  
 monitoring of, 329, 2372–2374, 2373t  
 in older men, 7e-1, 7e-2f, 7e-2t  
 regimens for, 2372
- Testosterone undecanoate, 2370t, 2371
- Testotoxicosis, 2362
- TET2 gene mutations, 135e-6, 670, 680, 680t
- Tetanospasm, 984
- Tetanus, 984  
 approach to the patient, 985, 985f  
 clinical features of, 985, 985f  
 complications of, 986  
 definition of, 984  
 diagnosis of, 985–986  
 epidemiology of, 984  
 etiology of, 984  
 global considerations in, 984, 986–987  
 incidence pre- and postvaccine, U.S., 785t, 984  
 neonatal, 984, 986–987  
 pathogenesis of, 984–985  
 prevention of, 29t, 787–788f, 986–987  
 prognosis of, 986, 986t  
 prophylaxis, for bite-wounds, 167e-3  
 treatment of, 986
- Tetanus, diphtheria, acellular pertussis (Tdap) vaccine  
 contraindications to, 789t  
 precautions for, 789t  
 recommended administration of  
 in adults, 787–788f, 980  
 in children, 980  
 in pregnancy, 51, 788f, 987  
 in travelers, 794
- Tetanus booster, for bite-wounds, 167e-3
- Tetanus-diphtheria (Td) vaccine  
 contraindications to, 789t  
 recommended administration of  
 in adults, 29t, 787–788t, 980  
 in cancer patient, 485t
- Tetanus immune globulin (TIG), 167e-3, 986
- Tetanus vaccine  
 for burn patient, 166e-3  
 for travelers, 794
- Tetany, in malabsorption syndromes, 1946t
- Tethered cord syndrome, 118, 2659
- Tetherin, 1218
- Tetrabenazine, 2611, 2621, 2622, 2624
- Tetracycline(s)  
 for acne rosacea, 352  
 for acne vulgaris, 352  
 for actinomycosis, 1091t  
 action of, 930–931, 931t, 932f, 943  
 adverse effects of, 938t, 943  
 cutaneous, 246e-7t, 360, 362, 379  
 folate deficiency, 646t  
 frequent, 246e-7t, 1380t  
 lupus syndrome, 2218t  
 nail disorders, 380  
 papilledema, 203f  
 phototoxicity, 389t  
 rare, 246e-7t  
 renal failure, 1380t  
 teeth discoloration, 236
- for balantidiasis, 1409  
 for *C. pneumoniae* infection, 1174  
 for *C. trachomatis* infection, 1171  
 for cholera, 1064  
 contraindications to, 1148  
 for donovanosis, 198e-2t  
 drug interactions of, 42t, 246e-2t, 246e-7t, 939t  
 for ehrlichiosis, 1160  
 for endemic treponematoses, 207e-2  
 in *H. pylori* eradication, 1042t, 1922, 1922t  
 indications for, 943  
 for *Legionella* infection, 1020t  
 for *M. hominis* infection, 926  
 for *M. pneumoniae* infections, 1164  
 for malaria, 1378t, 1380t  
 for meibomitis, 199  
 for parasitic infections, 246e-7t  
 pharmacology of, 1380t  
 for plague prophylaxis, 1075t  
 for plague treatment, 1074t  
 in pregnancy and lactation, 246e-7t, 937t  
 for psittacosis, 1173  
 for relapsing fever, 1148, 1148f  
 resistance to, 931t, 934, 1064  
 for Rocky Mountain spotted fever, 1157  
 for syphilis, 1139, 1139t  
 for tropical sprue, 1943
- Tetrahydrocannabinol (THC), 103e-25, 260t, 444e-4, 469e-2
- Tetrahydrofolate, 641, 641t
- Tetrahydrozoline, 473e-9t
- Tetralogy of Fallot  
 clinical features of, 400, 1526–1527  
 diagnosis of, 1527  
 hypoxia in, 248  
 murmur in, 51e-4f  
 pathophysiology of, 1526  
 repaired, ventricular arrhythmias in, 1495, 1495t  
 treatment of, 1527
- Tetrathiomolybdate, 2520, 2520t, 2625
- TF (tissue factor), 401, 401f
- Tg. *See* Thyroglobulin (Tg)
- TGF- $\alpha$ . *See* Transforming growth factor- $\alpha$  (TGF- $\alpha$ )
- TGF- $\beta$ . *See* Transforming growth factor- $\beta$  (TGF- $\beta$ )
- Thalamic Déjérine-Roussy syndrome, 2575
- Thalamus, 161, 211
- Thalassemia syndromes, 633, 633t, 637  
 $\alpha$  thalassemia, 633, 637–638, 638t  
 $\alpha$  thalassemia-1 trait, 638, 638t  
 $\alpha$  thalassemia-2 trait, 638, 638t  
 arthropathy in, 2242  
 $\beta$  thalassemia  
 arthropathy in, 2242  
 clinical features of, 637  
 genetic considerations in, 433f, 435, 633  
 $\beta$  thalassemia intermedia, 637, 637f  
 $\beta$  thalassemia major, 637